|Systematic (IUPAC) name|
|Licence data||US FDA:|
|Metabolism||Hepatic via CYP3A4|
|Half-life||1.8 (± 0.4) hours|
|PDB ligand ID||MK1 (, )|
|Mol. mass||613.79 g/mol|
|(what is this?)|
It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.
Unfortunately, indinavir wears off quickly after dosing, so requires very precise dosing every eight hours to thwart HIV from forming drug-resistant mutations, including resistances to other protease inhibitors. It has restrictions on what sorts of food may be eaten concurrently.
The most common side effects of indinavir include:
- Gastrointestinal disturbances (abdominal pain, diarrhea, nausea, vomiting)
- General malaise and fatigue
- Nephrolithiasis/urolithiasis (the formation of kidney stones), which sometimes may lead to more severe condition including kidney failure
- Metabolic alterations including hyperlipidemia (cholesterol or triglyceride elevations) and hyperglycemia
- Alterations in body shape (lipodystrophy), colloquially known as "Crix belly"
Indinavir inhibits urinary nitrous oxide production and may inhibit nitric oxide production. Treatment with this drug is frequently associated with renal abnormalities, sterile leukocyturia, and reduced creatinine clearance.
The Food and Drug Administration approved indinavir on March 13, 1996, making it the eighth approved antiretroviral. Indinavir is much more powerful than any prior antiretroviral drug; using it with dual NRTIs set the standard for treatment of HIV/AIDS and raised the bar on design and introduction of subsequent antiretroviral drugs. Protease inhibitors changed the very nature of the AIDS epidemic from one of a terminal illness to a somewhat manageable one.
- Liu, F.; Boross, P. I.; Wang, Y. F.; Tozser, J.; Louis, J. M.; Harrison, R. W.; Weber, I. T. (2005). "Kinetic, Stability, and Structural Changes in High-resolution Crystal Structures of HIV-1 Protease with Drug-resistant Mutations L24I, I50V, and G73S". Journal of Molecular Biology 354 (4): 789–800. doi:10.1016/j.jmb.2005.09.095. PMC 1403828. PMID 16277992.
- "WHO Model List of EssentialMedicines". World Health Organization. October 2013. Retrieved 22 April 2014.
- "Crixivan® (indinavir sulfate) Capsules. Prescribing Information. Revised December 2013". Merck & Co., Inc. Retrieved 6 February 2014.
- M. Eira, M. Araujo and A.C. Seguro. Urinary NO3 excretion and renal failure in indinavir-treated patients. Brazilian Journal of Medical and Biological Research (2006) 39: 1065-1070.
- Shankar SS, Dubé MP, Gorski JC, Klaunig JE, Steinberg HO. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J. 2005 Nov;150(5):933.
- Askin, D.; Eng, K. K.; Rossen, K.; Purick, R. M.; Wells, K. M.; Volante, R. P.; Reider, P. J. (1994). "Highly diastereoselective reaction of a chiral, non-racemic amide enolate with (S)-glycidyl tosylate. Synthesis of the orally active HIV-1 protease inhibitor L-735,524". Tetrahedron Letters 35 (5): 673. doi:10.1016/S0040-4039(00)75787-X.